Sermorelin timeline: what to expect week by week

Last updated 2026-07-25

What is the realistic sermorelin timeline from first dose to full effect?

Sermorelin is a growth-hormone-releasing hormone (GHRH) analog, not growth hormone itself. It works by prompting your own pituitary to pulse out GH, which is a fundamentally slower mechanism than injecting HGH directly. That difference drives the whole timeline. Week 1 to 2 is mostly adjustment. Some people feel nothing. Others notice more vivid dreams or slightly deeper sleep within the first several nights, since GHRH analogs are dosed at bedtime to work with the body's natural nocturnal GH pulse. Week 2 to 4 is when subjective sleep quality changes tend to show up for people who respond at all. This isn't universal. Nobody has a large, clean trial that says "73% of users report X by day 21"; the honest answer is that individual response varies and a lot of what's reported is self-observed, not measured in a lab. Month 2 to 3 is where lab markers start to move, if they're going to. A rise in serum IGF-1 is the standard proxy clinicians use to confirm the pituitary is responding, and it's typically checked at follow-up bloodwork rather than week one. Month 3 to 6 is the window where body composition changes (a bit less fat, a bit more lean tissue) become plausible to notice, assuming consistent nightly dosing and no gaps. This is not a fat-loss drug in the way people hope; it's a slow lever, not a switch. One related peptide study is worth naming honestly: a 2017 study in hypogonadal men using a growth hormone secretagogue found it raised serum IGF-1 levels over the treatment period ^[1], which is consistent with the general "labs move before the mirror does" pattern seen with GHRH-axis therapies.

How long until sermorelin starts working for sleep?

Sleep is usually the first thing people notice, and it's the most commonly reported early change in real-world use, generally somewhere in the first two to four weeks of nightly dosing. The mechanism reasoning behind this timing: sermorelin is injected subcutaneously before bed specifically because natural GH release is pulsatile and concentrated in early slow-wave sleep. Dosing at night is meant to amplify a pulse that's already happening, not create one from nothing. That said, sleep response is inconsistent between people. Some notice nothing different for a month. Others report a change in the first week. If you haven't noticed any difference in sleep or morning energy by 4 to 6 weeks of consistent dosing, that's worth flagging to your prescriber rather than assuming you just need more patience. Injection technique and timing matter here too. See sermorelin how to inject and sermorelin injection sites if you suspect technique is part of the problem.

When do IGF-1 levels actually change on sermorelin?

IGF-1 is the lab value prescribers use to confirm the pituitary is actually responding to sermorelin, since GH itself is too pulsatile and short-lived in blood to measure reliably day to day. Most protocols recheck IGF-1 at 8 to 12 weeks, not sooner, because a single early draw is noisy and doesn't tell you much. A 2017 study in the American Journal of Men's Health looked at growth hormone secretagogue treatment in hypogonadal men and found it raised serum IGF-1 levels during treatment ^[1]. That's a secretagogue study, not a sermorelin-specific trial, and it involved a specific population (hypogonadal men), so don't over-read it as a universal promise. It does support the general principle that this drug class moves IGF-1 measurably, which is the whole point of checking it. If IGF-1 hasn't moved from baseline by 3 months of consistent dosing, that's a real signal, more than impatience, and it's a reasonable point to revisit dose or adherence with the prescriber.

How long does it take to see body composition changes on sermorelin?

This is the slowest part of the timeline and the part most likely to disappoint people who came in expecting HGH-like results. Realistic expectation: 3 to 6 months of consistent dosing before any visible shift in body composition, and even then the effect size in the literature for GHRH-axis therapy is modest, not dramatic. A translational andrology and urology review on growth hormone secretagogues in hypogonadal males frames these agents as tools for managing body composition in men with low GH/IGF-1 status, not as general-purpose fat-loss or muscle-building agents for healthy adults ^[2]. That's an important distinction: the evidence base is built around people with a diagnosed deficiency, not people who are already healthy and want an edge. If your actual goal is fast, visible body composition change, sermorelin is the wrong tool and you should say that plainly to whoever is prescribing it. Compare this honestly against other options at mk 677 vs sermorelin.

Does sermorelin work faster or slower than HGH?

Slower, and that's by design, not a flaw. Injected HGH (somatropin) puts finished hormone directly into circulation, so its effect on IGF-1 and downstream tissue is more direct and generally faster to show up in labs. Sermorelin instead stimulates your pituitary to make and release GH itself, adding a biological step that HGH skips entirely. This matters for two reasons. First, sermorelin's effect is bounded by how much GH your own pituitary is still capable of producing; if pituitary reserve is severely damaged, sermorelin has less to work with. Second, sermorelin preserves the pulsatile, feedback-regulated pattern of natural GH release, while direct HGH injection overrides it. That physiological difference is part of why sermorelin's clinical history (as the discontinued brand Geref) was framed around diagnostic testing and mild adult GH insufficiency, not the kind of aggressive replacement seen with HGH itself ^[3]. Here's the honest table comparison people actually want:

What is Geref and why does sermorelin have FDA history other peptides don't?

Sermorelin was previously sold in the US under the brand name Geref. That's a real regulatory fact, and it's worth being precise about what happened to it: Geref was discontinued by its manufacturer, not pulled by the FDA for a safety failure. That distinction matters a lot in a market full of peptides that never had any formal FDA review at all. You can check current FDA-approved drug status yourself in the Drugs@FDA database ^[4]. As of now, sermorelin doesn't appear as an actively marketed FDA-approved product there; it exists in the current market almost entirely through compounding pharmacies. That compounding pathway has its own legal framework. Under 21 U.S.C. 353a, licensed pharmacies can compound a drug from bulk substances for an individual patient under specific conditions ^[5]. The FDA maintains a bulks list under 21 CFR 216.23 (for 503A pharmacy compounding) ^[6] and 21 CFR 216.24 (for 503B outsourcing facilities) ^[7], and separately publishes a running list of bulk drug substances nominated for compounding consideration ^[8]. Whether sermorelin sits on those lists, and under what conditions, is worth verifying directly with the pharmacy and prescriber rather than assuming it based on the older Geref history.

What happens if you stop sermorelin? Does the timeline reverse?

Yes, effects are not permanent, and this is one of the more honest and underdiscussed parts of the sermorelin conversation. Because sermorelin works by stimulating your own pituitary rather than replacing hormone outright, stopping the drug removes that stimulation and any gains built on it (sleep quality, modest IGF-1 elevation, small body composition shifts) tend to fade back toward your pre-treatment baseline over weeks to a few months. There's no large trial mapping out exactly how many weeks reversal takes for sermorelin specifically, and that's a real gap; the honest answer is "it likely tracks the same rough timescale as the original response, just in reverse," not a number pulled from a study. This is a good reason to think of sermorelin as an ongoing therapy you either continue or don't, not a short course that locks in permanent change. If dosing gaps or interruptions are a concern for you, it's worth reviewing potential interactions and adherence factors at sermorelin drug interactions.

How is sermorelin dosed and does dosing frequency change the timeline?

Sermorelin is typically dosed as a nightly subcutaneous injection, timed before bed to work with the body's natural sleep-associated GH pulse. Missed doses or inconsistent timing plausibly extend the timeline before you'd notice anything, since the whole mechanism depends on repeated nightly stimulation rather than a single large dose doing the work. Dose and protocol specifics (concentration, injection site rotation, timing precision) are a separate topic worth reading in full at sermorelin how to inject and sermorelin injection sites, since technique errors are a common, fixable reason people feel like "nothing is happening" at the 4 to 6 week mark. A 2006 clinical review in Clinical Interventions in Aging examined sermorelin's role in managing adult-onset growth hormone insufficiency and discusses it as an alternative approach to direct GH replacement, consistent with its slower, pituitary-dependent mechanism ^[3].

What does the research base actually say about sermorelin's timeline and effects?

The clinical literature on sermorelin itself is thinner than most people assume, and a lot of what circulates online leans on adjacent peptide and secretagogue research rather than sermorelin-specific trials. A 1999 BioDrugs review focused specifically on sermorelin's use in diagnosing and treating idiopathic growth hormone deficiency in children, which is actually one of its clearer historical use cases: as a diagnostic and treatment tool in pediatric GH deficiency, not as a general adult wellness therapy ^[9]. More recent work has looked at sermorelin in unexpected contexts: a 2021 paper in Annals of Translational Medicine explored sermorelin as a potentially effective drug for patients with recurrent glioma ^[10], a completely different application from body composition or anti-aging use, and a reminder that a molecule's research footprint can be broad without any of it supporting the claims people make about it in wellness marketing. A broader 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews covers therapeutic peptides in orthopaedics generally, including applications and challenges for the class sermorelin belongs to ^[11], and a 2026 Sports Medicine paper reviews safety and efficacy data (and gaps) across approved and unapproved peptide therapies used for musculoskeletal and athletic performance purposes ^[12]. Both are useful for understanding how thin the evidence base is once you move outside sermorelin's narrow, historically studied indications.

Why do some people never notice anything on sermorelin?

Because sermorelin's ceiling is set by your own pituitary's remaining capacity, individual response genuinely varies more than with direct HGH. If your pituitary is already producing adequate GH, adding a GHRH stimulus may not move the needle much, since the feedback system regulating GH release is still intact and active. This is a real and underdiscussed limitation, not a dosing failure. It's also one of the clearest arguments for baseline lab testing (IGF-1, and a clinical workup for GH insufficiency) before starting, so you and your prescriber have an actual number to compare against at the 8-to-12-week recheck rather than relying on how you feel. If you're a woman considering sermorelin, response patterns and safety considerations differ somewhat by sex hormone context; see sermorelin in women for specifics worth discussing with a prescriber before starting.

What's the honest sermorelin versus HGH answer for someone deciding between them?

If you have a diagnosed, lab-confirmed GH deficiency and your pituitary still has meaningful reserve, sermorelin is a reasonable, gentler starting point with a slower but more physiological timeline. If your pituitary function is severely compromised, or you need a faster, more predictable lab change, direct HGH is the more direct tool, at the cost of a different risk and monitoring profile and its own FDA-approved indications you'd need to qualify for. Sermorelin is not a faster or stronger version of HGH. It's a slower, indirect, self-regulating alternative, and its main real advantage is that it works with your body's own feedback loops rather than overriding them. That's also its main limitation: it can only do as much as your pituitary lets it. For a full side-by-side on mechanism, monitoring, and where each fits, read sermorelin as the primary reference, and use provider-reviewed sourcing rather than unregulated online sellers. Sermorelin Co's provider-reviewed protocols route prescriptions through licensed pharmacy partners rather than direct-to-consumer sales, which matters given how unregulated peptide sourcing has become in this market.

Frequently asked questions

How many weeks until sermorelin starts working?

Most people who respond notice sleep changes within 2 to 4 weeks. Lab markers like IGF-1 typically take 8 to 12 weeks to show a measurable shift, and body composition changes generally need 3 to 6 months of consistent nightly dosing before they're noticeable.

Is sermorelin as fast-acting as HGH injections?

No. HGH is finished hormone injected directly into circulation, so it tends to move IGF-1 and tissue effects faster. Sermorelin stimulates your own pituitary to release GH, an extra biological step that makes its effect slower and dependent on your remaining pituitary function.

Does sermorelin show results faster in some people than others?

Yes, individual response varies a lot, largely because sermorelin's ceiling is set by how much GH your own pituitary can still produce. People with more pituitary reserve tend to respond more clearly and possibly sooner than those with more limited reserve.

What happened to Geref, the original sermorelin brand?

Geref was the FDA-marketed brand name for sermorelin in the US. It was discontinued by its manufacturer rather than pulled for a safety problem. Sermorelin is not currently listed as an actively marketed FDA-approved product in the Drugs@FDA database.

Do sermorelin effects reverse after stopping treatment?

Yes. Because sermorelin works by stimulating your own pituitary rather than replacing hormone directly, stopping it removes that stimulation, and gains in sleep quality, IGF-1, or body composition tend to fade back toward baseline over weeks to a few months.

How is sermorelin timing different from HGH dosing schedules?

Sermorelin is typically injected nightly before bed to work with the body's natural sleep-associated GH pulse. HGH dosing schedules vary by indication and don't depend on the same natural pulsatile timing, since HGH is delivering finished hormone directly rather than stimulating a release.

When should I get bloodwork checked after starting sermorelin?

Most protocols recheck IGF-1 around 8 to 12 weeks after starting, since a single early draw is too noisy to be meaningful. Baseline labs before starting are also worth having, so you have a real number to compare the recheck against.

Can sermorelin help with body composition and fat loss?

Research on GH secretagogues in hypogonadal men has shown IGF-1 increases during treatment, and reviews frame these agents around managing body composition in men with low GH/IGF-1 status specifically, not as general fat-loss agents for healthy adults. Any effect is modest and slow, typically 3 to 6 months.

Is sermorelin legal and FDA-approved in the US right now?

Sermorelin doesn't currently appear as an actively marketed FDA-approved drug in the Drugs@FDA database. It's available primarily through compounding pharmacies operating under the 503A framework in 21 U.S.C. 353a, which allows compounding from bulk substances for individual patients under specific conditions.

What if I've been on sermorelin for a month and feel nothing?

That's not unusual and it's worth flagging to your prescriber rather than assuming you just need more time. It could reflect limited pituitary reserve, inconsistent nightly dosing, injection technique issues, or simply being a lower responder. A recheck of IGF-1 around the 8 to 12 week mark gives you an objective answer.

Does sermorelin work differently in women than in men?

Response patterns and safety considerations can differ somewhat by sex hormone context, and this is worth discussing directly with a prescriber rather than assuming a one-size approach. See a dedicated review of sermorelin in women for the specifics before starting.

How does sermorelin's timeline compare to other GH secretagogues like MK-677?

MK-677 is an oral ghrelin mimetic with a different mechanism and dosing schedule than injectable sermorelin, and the two aren't directly interchangeable in terms of expected timeline or effect profile. A direct comparison is the better resource than trying to extrapolate one timeline onto the other.

Sources

1. American Journal of Men's Health, 2017: Growth hormone secretagogue treatment in hypogonadal men raised serum IGF-1 levels during the treatment period.
2. Translational Andrology and Urology, 2020: Growth hormone secretagogues are reviewed as tools for managing body composition specifically in hypogonadal males, not as general-purpose agents for healthy adults.
3. Clinical Interventions in Aging, 2006: Sermorelin is examined as an alternative approach to management of adult-onset growth hormone insufficiency, consistent with its pituitary-dependent mechanism.
4. FDA, Drugs@FDA database: Used to verify current FDA-approved drug marketing status for sermorelin and HGH products.
5. 21 U.S.C. 353a, pharmacy compounding: Licensed pharmacies may compound a drug from bulk substances for an individual patient under specific statutory conditions.
6. 21 CFR 216.23, the 503A Bulks List: FDA maintains a list of bulk drug substances that can be used in compounding under section 503A.
7. 21 CFR 216.24, the 503B Bulks List: FDA maintains a separate bulk drug substances list applicable to 503B outsourcing facilities.
8. FDA, bulk drug substances nominated for use in compounding: FDA publishes a running list of bulk drug substances nominated for compounding consideration.
9. BioDrugs, 1999: Sermorelin's use has been reviewed specifically in the diagnosis and treatment of idiopathic growth hormone deficiency in children.
10. Annals of Translational Medicine, 2021: Sermorelin has been studied as a potentially effective drug for patients with recurrent glioma, a use unrelated to body composition or anti-aging claims.
11. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 2026: Reviews therapeutic peptides in orthopaedics, including applications and challenges relevant to the peptide class sermorelin belongs to.
12. Sports Medicine (Auckland, N.Z.), 2026: Reviews safety and efficacy data and evidence gaps across approved and unapproved peptide therapies used for musculoskeletal injury and athletic performance.